Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Blinklab Limited ( (AU:BB1) ) has provided an update.
BlinkLab Limited has announced significant progress in its clinical trials for autism and ADHD diagnostics during the April-June 2025 quarter. Key achievements include nearing completion of the pilot phase of the U.S. autism trial, expansion of ADHD trials in Europe, and securing U.S. IRB approval for the main phase of its FDA study. The company also raised $7.66 million to support these initiatives, positioning itself as a leader in the digital diagnostic space by offering a scalable platform for both conditions. This progress underscores BlinkLab’s commitment to addressing critical diagnostic gaps and providing earlier intervention opportunities for neurodevelopmental conditions.
More about Blinklab Limited
BlinkLab Limited is a leading digital healthcare company specializing in AI-powered diagnostics for neurodevelopmental conditions. The company focuses on developing a unified digital diagnostic platform for autism and ADHD, targeting both the U.S. and European healthcare markets.
Average Trading Volume: 281,686
Technical Sentiment Signal: Strong Buy
See more data about BB1 stock on TipRanks’ Stock Analysis page.